Theravance Biopharma announced a major corporate restructuring after its norepinephrine reuptake inhibitor ampreloxetine failed a Phase 3 study in symptomatic neurogenic orthostatic hypotension and in a later subgroup, triggering a strategic pivot. The company will wind down its R&D organization, cut approximately 50% of its workforce, and refocus on commercial activities tied to its approved respiratory product, Yupelri. Management said the moves aim to preserve cash and extend runway; analysts and investors will watch how asset wind‑downs and potential M&A options unfold.